Antonio joined Inveready in 2019. As Investment Director, he leads deal sourcing, due diligence, and portfolio management.

He currently serves on the boards of Atlas Molecular Pharma, Galgo Medical and Nanoligent

Prior to Inveready, Antonio held roles in technology transfer and business development across research institutions and startups, driving academic spin-offs and leading licensing and collaboration agreements with biotech and pharmaceutical companies.